Professor Anna deFazio

Sydney West Chair in Translational Cancer Research
Obstetrics, Gynaecology and Neonatology, Westmead Clinical School
Westmead Millennium Institute for Medical Research

Telephone +61 2 9845 7376

Website Related website

Map

Selected grants

2015

  • Novel Treatment Targets in Low-Grade Serous Ovarian Cancer; deFazio A; Cancer Council New South Wales/Research Project Grants.

2014

  • Essential clinical annotation for NSW Biobanks through data integration using State and Commonwealth datasets; deFazio A; Cancer Institute New South Wales/Biobanking Stakeholder Network Funding.
  • NanoString nCounter Platform; deFazio A, Alexander I, Booth D, Byrne J, Christodoulou J, Clarke C, Cunningham A, George J, Graham J, Harman A, Liddle C, Mann G; National Health and Medical Research Council (NHMRC)/Equipment Grants.

2013

  • Automated in situ analysis capacity for translational cancer research; Byrne J, Reddel R, Haber M, Norris M, deFazio A; Cancer Institute New South Wales/Equipment Grant.
  • Multidisciplinary Ovarian Cancer Outcomes Group; Pike M, deFazio A; US Department of Defence (USA)/Ovarian Cancer Research Program.
  • IncuCyte ZOOM; Rizos H, deFazio A, Mann G, Henderson B; DVC Research/Equipment Grant.

2012

  • The Ovarian Cancer Prognosis and Lifestyle (OPAL) Study; deFazio A, Webb P; National Health and Medical Research Council (NHMRC)/Project Grants.
  • Enhancement of the Gynaecological Oncology Biobank at Westmead and creation of a Sydney-West Translational Cancer Research Centre (SW-TCRC) Biospecimens Hub.; deFazio A; Cancer Institute New South Wales/Research Infrastructure Grant.
  • Clinical data linkage for NSW biobanks; deFazio A; Cancer Institute New South Wales/Biobanking Stakeholder Network Funding.
  • Molecular markers of relapse and treatment response in ovarian cancer; deFazio A, Harnett P, Bowtell D; National Health and Medical Research Council (NHMRC)/Project Grants.

2011

  • Australian Ovarian Cancer Study (AOCS); deFazio A, Bowtell D; National Health and Medical Research Council (NHMRC)/Enabling Grants.

2010

  • Response to Chemotherapy in Ovarian Cancer; deFazio A, Gurney H, Chenevix-Trench G, Haber M, Gurney H, Harnett P; Cancer Australia/Priority Driven Collaborative Cancer Research Scheme.
  • Pathways of malignant progression in ovarian cancer; deFazio A, Bowtell D, Harnett P, Hogg R, Russell P; Cancer Council New South Wales/Research Project Grants.
  • Australasian Biospecimen Network-Oncology; deFazio A; National Health and Medical Research Council (NHMRC)/Enabling Grants.
  • Genomic determinants of chemosensitivity in ovarian cancer; deFazio A, Bowtell D, Harnett P; Cancer Australia/Priority Driven Collaborative Cancer Research Scheme.

2009

  • Ovulation-related gene expression signature dysregulated in progression to cancer; deFazio A, Emmanuel C; Marsha Rivkin Centre for Ovarian Cancer Research (USA)/Pilot Study Program.
  • High-Throughput virtual microscopy and data warehouse system; Mann G, Schifter M, Balleine R, George J, Henderson B, Clarke C, Catchpoole D, deFazio A; Cancer Institute New South Wales/Equipment Grant.

2007

  • Chemo-sensitising pathways in ovarian cancer; Russell P, deFazio A, Harnett P, Russell P; Cancer Council New South Wales/Research Project Grants.

2006

  • Microarray-targeted candidate gene approach to finding ovarian cancer susceptibility genes; Chenevix-Trench G, Gertig D, deFazio A; National Health and Medical Research Council (NHMRC)/Project Grants.

2000

  • Transgenomic WAVE 2100 denaturing HPLC system for DNA variant analysis; Farrell G, Clarke C, Cunningham A, deFazio A, Kirk J, Leary J, Liddle C, Manolios N, Mitchell P, Stewart G, Mann G; National Health and Medical Research Council (NHMRC)/Equipment Grants.
  • Gluthathione peroxidase and breast cancer susceptibility; deFazio A; US Army Research Laboratory (USA)/Research Grant.
  • Mechanisms underlying the protective effects of tamoxifen on normal mammary gland; deFazio A, Clarke C; Cancer Council New South Wales/Research Project Grants.

Selected publications

Download citations: PDF RTF Endnote

Journals

  • Hedditch, E., Gao, B., Russell, A., Li, Y., Emmanuel, C., Beesley, J., Johnatty, S., Chen, X., Harnett, P., George, J., deFazio, A., et al (2014). ABCA transporter gene expression and poor outcome in epithelial ovarian cancer. Journal of the National Cancer Institute, 106(7), 1-11. [More Information]
  • Butow, P., Price, M., Bell, M., Webb, P., deFazio, A., Friedlander, M. (2014). Caring for women with ovarian cancer in the last year of life: A longitudinal study of caregiver quality of life, distress and unmet needs. Gynecologic Oncology, 132(3), 690-697. [More Information]
  • Dixon, S., Ibiebele, T., Protani, M., Beesley, J., deFazio, A., Crandon, A., Gard, G., Rome, R., Webb, P., Nagle, C. (2014). Dietary folate and related micronutrients, folate-metabolising genes, and ovarian cancer survival. Gynecologic Oncology, 132(3), 566-572. [More Information]
  • Au-Yeung, G., Webb, P., deFazio, A., Feredaye, S., Bressel, M., Mileshkin, L. (2014). Impact of obesity on chemotherapy dosing for women with advanced stage serous ovarian cancer in the Australian Ovarian Cancer Study (AOCS). Gynecologic Oncology, 133(1), 16-22. [More Information]
  • Gao, B., Russell, A., Beesley, J., Chen, X., Healey, S., Henderson, M., Wong, K., Emmanuel, C., Galletta, L., Johnatty, S., Harnett, P., Balleine, R., deFazio, A., Hung, J., Chiew, Y., et al (2014). Paclitaxel sensitivity in relation to ABCB1 expression, efflux and single nucleotide polymorphisms in ovarian cancer. Scientific Reports, 4, 1-9. [More Information]
  • Block, M., Charbonneau, B., Vierkant, R., Fogarty, Z., Bamlet, W., Pharoah, P., Chenevix-Trench, G., Rossing, M., Cramer, D., Pearce, C., deFazio, A., et al (2014). Variation in NF-κB signaling pathways and survival in invasive epithelial ovarian cancer. Cancer Epidemiology, Biomarkers and Prevention, 23(7), 1421-1427. [More Information]
  • Johnatty, S., Beesley, J., Gao, B., Chen, X., Lu, Y., Law, M., Henderson, M., Russell, A., Hedditch, E., Emmanuel, C., deFazio, A., et al (2013). ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: A comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas. Gynecologic Oncology, 131(1), 8-14. [More Information]
  • White, K., Vierkant, R., Fogarty, Z., Charbonneau, B., Block, M., Pharoah, P., Chenevix-Trench, G., Rossing, M., Cramer, D., Pearce, C., deFazio, A., et al (2013). Analysis of Over 10,000 Cases Finds No Association between Previously Reported Candidate Polymorphisms and Ovarian Cancer Outcome. Cancer Epidemiology, Biomarkers and Prevention, 22(5), 987-992. [More Information]
  • Baumbusch, L., Helland, A., Wang, Y., Liestöl, K., Schaner, M., Holm, R., Etemadmoghadam, D., Alsop, K., Brown, P., Mitchell, G., deFazio, A., et al (2013). High Levels of Genomic Aberrations in Serous Ovarian Cancers Are Associated with Better Survival. PloS One, 8(1), 1-8. [More Information]
  • Sieh, W., Kobel, M., Longacre, T., Bowtell, D., deFazio, A., Goodman, M., Hogdall, E., Deen, S., Wentzensen, N., Moysich, K., et al (2013). Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. The Lancet Oncology, 14(9), 853-862. [More Information]
  • George, J., Alsop, K., Etemadmoghadam, D., Hondow, H., Mikeska, T., Dobrovic, A., deFazio, A., Smyth, G., Levine, D., Mitchell, G., et al (2013). Nonequivalent gene expression and copy number alterations in high-grade serous ovarian cancers with BRCA1 and BRCA2 mutations. Clinical Cancer Research, 19(13), 3474-3484. [More Information]
  • Jordan, S., Steer, C., deFazio, A., Quinn, M., Obermair, A., Friedlander, M., Francis, J., O'Brien, S., Goss, G., Wyld, D., et al (2013). Patterns of chemotherapy treatment for women with invasive epithelial ovarian cancer - a population-based study. Gynecologic Oncology, 129(2), 310-317. [More Information]
  • Price, M., Bell, M., Sommeijer, D., Friedlander, M., Stockler, M., deFazio, A., Webb, P., Butow, P. (2013). Physical symptoms, coping styles and quality of life in recurrent ovarian cancer: A prospective population-based study over the last year of life. Gynecologic Oncology, 130(1), 162-168. [More Information]
  • Verhaak, R., Tamayo, P., Yang, J., Hubbard, D., Zhang, H., Creighton, C., Fereday, S., Lawrence, M., Carter, S., Mermel, C., deFazio, A., et al (2013). Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. Journal of Clinical Investigation, 123(1), 517-525. [More Information]
  • Alsop, K., Fereday, S., Meldrum, C., deFazio, A., Emmanuel, C., George, J., Dobrovic, A., Birrer, M., Webb, P., Stewart, C., et al (2012). BRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutation-Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group. Journal of Clinical Oncology, 30(21), 2654-2663. [More Information]
  • Lu, Y., Chen, X., Beesley, J., Johnatty, S., deFazio, A., Lambrechts, S., Lambrechts, D., Despierre, E., Vergotes, I., Chang-Claude, J., et al (2012). Genome-Wide Association Study for Ovarian Cancer Susceptibility Using Pooled DNA. Twin Research and Human Genetics, 15(5), 615-623. [More Information]
  • Cowin, P., George, J., Fereday, S., Loehrer, E., Van Loo, P., Cullinane, C., Etemadmoghadam, D., Ftouni, S., Galletta, L., Anglesio, M., Harnett, P., deFazio, A., et al (2012). LRP1B Deletion in High-Grade Serous Ovarian Cancers Is Associated with Acquired Chemotherapy Resistance to Liposomal Doxorubicin. Cancer Research, 72(16), 4060-4073. [More Information]
  • Wang, Z., Birkbak, N., Culhane, A., Drapkin, R., Fatima, A., Tian, R., Schwede, M., Alsop, K., Daniels, K., Piao, H., deFazio, A., et al (2012). Profiles of Genomic Instability in High-Grade Serous Ovarian Cancer Predict Treatment Outcome. Clinical Cancer Research, 18(20), 5806-5815. [More Information]
  • Emmanuel, C., Gava, N., Kennedy, C., Balleine, R., Sharma, R., Wain, G., Brand, A., Hogg, R., Etemadmoghadam, D., George, J., Clarke, C., Harnett, P., deFazio, A., et al (2011). Comparison of Expression Profiles in Ovarian Epithelium In Vivo and Ovarian Cancer Identifies Novel Candidate Genes Involved in Disease Pathogenesis. PloS One, 6(3), e17617-1-e17617-18. [More Information]
  • Hunter, S., Anglesio, M., Sharma, R., Gilks, B., Melnyk, N., Chiew, Y., deFazio, A., Longacre, T., Huntsman, D., Gorringe, K., et al (2011). Copy Number Aberrations in Benign Serous Ovarian Tumors: A Case for Reclassification? Clinical Cancer Research, 17(23), 7273-7282. [More Information]
  • Helland, A., Anglesio, M., George, J., Cowin, P., Johnstone, C., House, C., Sheppard, K., Etemadmoghadam, D., Melnyk, N., Rustgi, A., deFazio, A., et al (2011). Deregulation of MYCN, LIN28B and LET7 in a Molecular Subtype of Aggressive High-Grade Serous Ovarian Cancers. PloS One, 6(4), 1-9. [More Information]
  • Anglesio, M., George, J., Kulbe, H., Friedlander, M., Rischin, D., Lemech, C., Power, J., Coward, J., Cowin, P., House, C., deFazio, A., et al (2011). IL6-STAT3-HIF Signaling and Therapeutic Response to the Angiogenesis Inhibitor Sunitinib in Ovarian Clear Cell Cancer. Clinical Cancer Research, 17(8), 2538-2548. [More Information]
  • Huang, S., Johnatty, S., Gamazon, E., Kyung Im, H., Ziliak, D., Duan, S., Zhang, W., O' Kistner, E., Chen, P., Beesley, J., deFazio, A., et al (2011). Platinum Sensitivity-Related Germline Polymorphism Discovered via a Cell-Based Approach and Analysis of Its Association with Outcome in Ovarian Cancer Patients. Clinical Cancer Research, 17(16), 5490-5500. [More Information]
  • Nagle, C., Francis, J., Nelson, A., Zorbas, H., Luxford, K., deFazio, A., Fereday, S., Bowtell, D., Green, A., Webb, P. (2011). Reducing Time to Diagnosis Does Not Improve Outcomes for Women With Symptomatic Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group. Journal of Clinical Oncology, 29(16), 2253-2258. [More Information]
  • McConechy, M., Anglesio, M., Kalloger, S., Yang, W., Senz, J., Chow, C., Heravi-Moussavi, A., Morin, G., deFazio, A., Mes-Masson, A., et al (2011). Subtype-specific mutation of PPP2R1A in endometrial and ovarian carcinomas. Journal of Pathology, 223(5), 567-573. [More Information]
  • Pharoah, P., Palmieri, R., Ramus, S., Gayther, S., Andrulis, I., Anton-Culver, H., Antonenkova, N., Antoniou, A., Goldgar, D., deFazio, A., Gao, B., Harnett, P., et al (2011). The Role of KRAS rs61764370 in Invasive Epithelial Ovarian Cancer: Implications for Clinical Testing. Clinical Cancer Research, 17(11), 3742-3750. [More Information]
  • Johal, H., Faedo, M., Faltas, J., Lau, A., Mousina, R., Cozzi, P., deFazio, A., Rawlinson, W. (2010). DNA of mouse mammary tumor virus-like virus is present in human tumors influenced by hormones. Journal of Medical Virology, 82(6), 1044-1050. [More Information]
  • Ahmed Ashoure, A., Etemadmoghadam, D., Temple, J., Lynch, A., Riad, M., Sharma, R., Stewart, C., Fereday, S., Caldas, C., deFazio, A., et al (2010). Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. Journal of Pathology, 221(1), 49-56. [More Information]
  • Johnatty, S., Beesley, J., Chen, X., MacGregor, S., Duffy, D., Spurdle, A., deFazio, A., Gava, N., Webb, P., Rossing, M., et al (2010). Evaluation of candidate stromal epithelial cross-talk genes identifies association between risk of serous ovarian cancer and TERT, a cancer susceptibility "hot-spot". PLoS Genetics, 6(7), e1001016 - 1-e1001016 - 10. [More Information]
  • Hudson, T., Anderson, W., Aretz, A., Barker, A., Bell, C., Bernabe, R., Bhan, M., Calvo, F., Eerola, I., Gerhard, D., deFazio, A., Kench, J., et al (2010). International network of cancer genome projects. Nature, 464, 993-998. [More Information]
  • Byrne, J., Maleki, S., Hardy, J., Gloss, B., Murali, R., Scurry, J., Fanayan, S., Emmanuel, C., Hacker, N., Sutherland, R., deFazio, A., et al (2010). MAL2 and tumor protein D52 (TPD52) are frequently overexpressed in ovarian carcinoma, but differentially associated with histological subtype and patient outcome. BMC Cancer, 10(497), 1-11. [More Information]
  • Gordon, L., Scuffham, P., Beesley, V., Green, A., deFazio, A., Wyld, D., Clavarino, A., Australian Ovarian Cancer Study Group, (., Webb, P. (2010). Medical costs and outcomes for Australian women with ovarian cancer: a patient-level analysis over 2.5 years. International Journal of Gynecological Cancer, 20(5), 757-765. [More Information]
  • Price, M., Butow, P., Costa, D., King, M., Aldridge, L., Fardell, J., deFazio, A., Webb, P. (2010). Prevalence and predictors of anxiety and depression in women with invasive ovarian cancer and their caregivers. Medical Journal of Australia, 193(5), S52-S57. [More Information]
  • Etemadmoghadam, D., deFazio, A., Beroukhim, R., Mermel, C., George, J., Getz, G., Tothill, R., Okamoto, A., Raeder, M., Harnett, P., Chiew, Y., et al (2009). Integrated genome-wide DMA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas. Clinical Cancer Research, 15(4), 1417-1427. [More Information]
  • Shah, S., Kobel, M., Senz, J., Morin, R., Clarke, B., Wiegand, K., Leung, G., Zayed, A., deFazio, A., Bowtell, D. (2009). Mutation of FOXL2 in granulosa-cell tumors of the ovary. New England Journal of Medicine, 360(26), 2719-2729. [More Information]
  • Johnatty, S., Beesley, J., Chen, X., Spurdle, A., deFazio, A., Webb, P., Goode, E., Rider, D., Vierkant, R., Anderson, S. (2009). Polymorphisms in the FGF2 Gene and Risk of Serous Ovarian Cancer: Results From the Ovarian Cancer Association Consortium. Twin Research and Human Genetics, 12(3), 269-275. [More Information]
  • Price, M., Zachariae, R., Butow, P., deFazio, A., Patel (nee Chauhan), D., Espie, C., Friedlander, M., Webb, P. (2009). Prevalence and predictors of insomnia in women with invasive ovarian cancer: Anxiety a major factor. European Journal of Cancer, 45(18), 3262-3270. [More Information]
  • Johnatty, S., Beesley, J., Paul, J., Fereday, S., Spurdle, A., Webb, P., Byth, K., Marsh, S., McLeod, H., AOCS, S., Harnett, P., deFazio, A., et al (2008). ABCB1 (MDR 1) polymorphisms and progression-free survival among women with ovarian cancer following paclitaxel/carboplatin chemotherapy. Clinical Cancer Research, 14(17), 5594-5601.
  • Scurr, L., Guminski, A., Chiew, Y., Balleine, R., Sharma, R., Lei, Y., Pryor, K., Wain, G., Brand, A., Byth, K., Kennedy, C., Rizos, H., Harnett, P., deFazio, A. (2008). Ankyrin Repeat Domain 1, ANKRD1, a Novel Determinant of Cisplatin Sensitivity Expressed in Ovarian Cancer. Clinical Cancer Research, 14(21), 6924-6932. [More Information]
  • Gava, N., Clarke, C., Bye, C., Byth Wilson, K., deFazio, A. (2008). Global gene expression profiles of ovarian surface epithelial cells in vivo. Journal of Molecular Endocrinology, 40, 281-296. [More Information]
  • Anglesio, M., Arnold, J., George, J., Tinker, A., Tothill, R., Waddell, N., Simms, L., Locandro, B., Fereday, S., Traficante, N., Russell, P., deFazio, A., et al (2008). Mutation of ERBB2 provides a novel alternative mechanism for the ubiquitous activation of RAS-MAPK in ovarian serous low malignant potential tumors. Molecular Cancer Research, 6(11), 1678-1690. [More Information]
  • Tothill, R., Tinker, A., George, J., Brown, R., Fox, S., Lade, S., Johnson,, D., Trivett, M., Etemadmoghadam, D., Locandro, B., deFazio, A., et al (2008). Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clinical Cancer Research, 14(16), 5198-5208. [More Information]
  • O'Brien, P., Davies, M., Scurry, J., Smith, A., Barton, C., Henderson, M., Saunders, D., Gloss, B., Patterson, K., et, A., Murali, R., Scolyer, R., Scurr, L., deFazio, A. (2008). The E3 ubiquitin ligase EDD is an adverse prognostic factor for serous epithelial ovarian cancer and modulates cisplatin resistance in vitro. British Journal of Cancer, 98(6), 1085-1093. [More Information]
  • Krypuy, M., Ahmed Ashoure, A., Etemadmoghadam, D., Hyland, S., deFazio, A., Fox, S., Brenton, J., Bowtell, D., Dobrovic, A. (2007). High resolution melting for mutation scanning of TP53 exons 5-8. BMC Cancer, 7(open access), 1-13. [More Information]
  • Greenman, C., Vastrik, I., Cahill, D., Goldstraw, P., Brasseur, F., Looijenga, L., Weber, B., Chiew, Y., deFazio, A., Greaves, M., et al (2007). Patterns of somatic mutation in human cancer genomes. Nature, 446(7132), 153-158. [More Information]
  • Catchpoole, D., deFazio, A., Devereaux, L., Hof, M., Schmidt, C., Thorne, H., Zeps, N., Fleming, M. (2007). The importance of biorepository networks: The Australasian Biospecimen Network-Oncology. Australian Journal of Medical Science, 28(1), 16-20.
  • Guminski, A., Balleine, R., Chiew, Y., Webster, L., Tapner, M., Farrell, G., Harnett, P., deFazio, A. (2006). MRP2 (ABCC2) and cisplatin sensitivity in hepatocytes and human ovarian carcinoma. Gynecologic Oncology, 100(2), 239-246. [More Information]
  • Mote, P., Arnett-Mansfield, R., Gava, N., deFazio, A., Mulac-Jericevic, B., Conneely, O., Clarke, C. (2006). Overlapping and distinct expression of progesterone receptors A and B in mouse uterus and mammary gland during the estrous cycle. Endocrinology, 147(12), 5503-5512. [More Information]
  • Aghmesheh, M., Edwards, L., Clarke, C., Byth Wilson, K., Katzenellenbogen, B., Russell, P., Friedlander, M., Tucker, K., deFazio, A. (2005). Expression of steroid hormone receptors in BRCA1-associated ovarian carcinomas. Gynecologic Oncology, 97(1), 16-25. [More Information]
  • Byrne, J., Balleine, R., Fejzo, M., Mercieca, J., Chiew, Y., Livnat, Y., St.Heaps, L., Peters, G., Byth Wilson, K., Karlan, B., Harnett, P., deFazio, A., et al (2005). Tumor protein D52 (TPD52) is overexpressed and a gene amplification target in ovarian cancer. International Journal of Cancer, 117(6), 1049-54. [More Information]
  • Balleine, R., Earls, P., Webster, L., Mote, P., deFazio, A., Harnett, P., Clarke, C. (2004). Expression Of Progesterone Receptor A And B Isoforms In Low-Grade Endometrial Stromal Sarcoma. International Journal of Gynecological Pathology, 23(2), 138-144.
  • Gava, N., Clarke, C., Byth Wilson, K., Arnett-Mansfield, R., deFazio, A. (2004). Expression Of Progesterone Receptors A And B In The Mouse Ovary During The Estrous Cycle. Endocrinology, 145(7), 3487-3494.
  • Arnett-Mansfield, R., deFazio, A., Mote, P., Clarke, C. (2004). Subnuclear Distribution Of Progesterone Receptors A And B In Normal And Malignant Endometrium. Journal of Clinical Endocrinology and Metabolism, 89(3), 1429-1442.
  • Guminski, A., Harnett, P., deFazio, A. (2001). Carboplatin and paclitaxel interact antagonistically in a megakaryoblast cell line - a potential mechanism for paclitaxel-mediated sparing of carboplatin-induced thrombocytopenia. Cancer Chemotherapy and Pharmacology, 48(3), 229-234.
  • Guminski, A., deFazio, A., Harnett, P. (2001). New genetics and cancer chemotherapy. Today's Life Science (Australia), 13(2), 36-40.
  • deFazio, A., Chiew, Y., Sini, R., Janes, P., Sutherland, R. (2000). Expression of c-erbB receptors, heregulin and oestrogen receptor in human breast cell lines. International Journal of Cancer, 87(4), 487-498.
  • Davis, T., Kennedy, C., Chiew, Y., Clarke, C., deFazio, A. (2000). Histone deacetylase inhibitors decrease proliferation and modulate cell cycle gene expression in normal mammary epithelial cells. Clinical Cancer Research, 6(11), 4334-4342.

Patents

  • deFazio, A., Harnett, P., Guminski, A. (2005). Patent Families: Determinants of sensitivity to chemotherapeutic agents. Patent No. 2005316200.

2014

  • Hedditch, E., Gao, B., Russell, A., Li, Y., Emmanuel, C., Beesley, J., Johnatty, S., Chen, X., Harnett, P., George, J., deFazio, A., et al (2014). ABCA transporter gene expression and poor outcome in epithelial ovarian cancer. Journal of the National Cancer Institute, 106(7), 1-11. [More Information]
  • Butow, P., Price, M., Bell, M., Webb, P., deFazio, A., Friedlander, M. (2014). Caring for women with ovarian cancer in the last year of life: A longitudinal study of caregiver quality of life, distress and unmet needs. Gynecologic Oncology, 132(3), 690-697. [More Information]
  • Dixon, S., Ibiebele, T., Protani, M., Beesley, J., deFazio, A., Crandon, A., Gard, G., Rome, R., Webb, P., Nagle, C. (2014). Dietary folate and related micronutrients, folate-metabolising genes, and ovarian cancer survival. Gynecologic Oncology, 132(3), 566-572. [More Information]
  • Au-Yeung, G., Webb, P., deFazio, A., Feredaye, S., Bressel, M., Mileshkin, L. (2014). Impact of obesity on chemotherapy dosing for women with advanced stage serous ovarian cancer in the Australian Ovarian Cancer Study (AOCS). Gynecologic Oncology, 133(1), 16-22. [More Information]
  • Gao, B., Russell, A., Beesley, J., Chen, X., Healey, S., Henderson, M., Wong, K., Emmanuel, C., Galletta, L., Johnatty, S., Harnett, P., Balleine, R., deFazio, A., Hung, J., Chiew, Y., et al (2014). Paclitaxel sensitivity in relation to ABCB1 expression, efflux and single nucleotide polymorphisms in ovarian cancer. Scientific Reports, 4, 1-9. [More Information]
  • Block, M., Charbonneau, B., Vierkant, R., Fogarty, Z., Bamlet, W., Pharoah, P., Chenevix-Trench, G., Rossing, M., Cramer, D., Pearce, C., deFazio, A., et al (2014). Variation in NF-κB signaling pathways and survival in invasive epithelial ovarian cancer. Cancer Epidemiology, Biomarkers and Prevention, 23(7), 1421-1427. [More Information]

2013

  • Johnatty, S., Beesley, J., Gao, B., Chen, X., Lu, Y., Law, M., Henderson, M., Russell, A., Hedditch, E., Emmanuel, C., deFazio, A., et al (2013). ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: A comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas. Gynecologic Oncology, 131(1), 8-14. [More Information]
  • White, K., Vierkant, R., Fogarty, Z., Charbonneau, B., Block, M., Pharoah, P., Chenevix-Trench, G., Rossing, M., Cramer, D., Pearce, C., deFazio, A., et al (2013). Analysis of Over 10,000 Cases Finds No Association between Previously Reported Candidate Polymorphisms and Ovarian Cancer Outcome. Cancer Epidemiology, Biomarkers and Prevention, 22(5), 987-992. [More Information]
  • Baumbusch, L., Helland, A., Wang, Y., Liestöl, K., Schaner, M., Holm, R., Etemadmoghadam, D., Alsop, K., Brown, P., Mitchell, G., deFazio, A., et al (2013). High Levels of Genomic Aberrations in Serous Ovarian Cancers Are Associated with Better Survival. PloS One, 8(1), 1-8. [More Information]
  • Sieh, W., Kobel, M., Longacre, T., Bowtell, D., deFazio, A., Goodman, M., Hogdall, E., Deen, S., Wentzensen, N., Moysich, K., et al (2013). Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. The Lancet Oncology, 14(9), 853-862. [More Information]
  • George, J., Alsop, K., Etemadmoghadam, D., Hondow, H., Mikeska, T., Dobrovic, A., deFazio, A., Smyth, G., Levine, D., Mitchell, G., et al (2013). Nonequivalent gene expression and copy number alterations in high-grade serous ovarian cancers with BRCA1 and BRCA2 mutations. Clinical Cancer Research, 19(13), 3474-3484. [More Information]
  • Jordan, S., Steer, C., deFazio, A., Quinn, M., Obermair, A., Friedlander, M., Francis, J., O'Brien, S., Goss, G., Wyld, D., et al (2013). Patterns of chemotherapy treatment for women with invasive epithelial ovarian cancer - a population-based study. Gynecologic Oncology, 129(2), 310-317. [More Information]
  • Price, M., Bell, M., Sommeijer, D., Friedlander, M., Stockler, M., deFazio, A., Webb, P., Butow, P. (2013). Physical symptoms, coping styles and quality of life in recurrent ovarian cancer: A prospective population-based study over the last year of life. Gynecologic Oncology, 130(1), 162-168. [More Information]
  • Verhaak, R., Tamayo, P., Yang, J., Hubbard, D., Zhang, H., Creighton, C., Fereday, S., Lawrence, M., Carter, S., Mermel, C., deFazio, A., et al (2013). Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. Journal of Clinical Investigation, 123(1), 517-525. [More Information]

2012

  • Alsop, K., Fereday, S., Meldrum, C., deFazio, A., Emmanuel, C., George, J., Dobrovic, A., Birrer, M., Webb, P., Stewart, C., et al (2012). BRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutation-Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group. Journal of Clinical Oncology, 30(21), 2654-2663. [More Information]
  • Lu, Y., Chen, X., Beesley, J., Johnatty, S., deFazio, A., Lambrechts, S., Lambrechts, D., Despierre, E., Vergotes, I., Chang-Claude, J., et al (2012). Genome-Wide Association Study for Ovarian Cancer Susceptibility Using Pooled DNA. Twin Research and Human Genetics, 15(5), 615-623. [More Information]
  • Cowin, P., George, J., Fereday, S., Loehrer, E., Van Loo, P., Cullinane, C., Etemadmoghadam, D., Ftouni, S., Galletta, L., Anglesio, M., Harnett, P., deFazio, A., et al (2012). LRP1B Deletion in High-Grade Serous Ovarian Cancers Is Associated with Acquired Chemotherapy Resistance to Liposomal Doxorubicin. Cancer Research, 72(16), 4060-4073. [More Information]
  • Wang, Z., Birkbak, N., Culhane, A., Drapkin, R., Fatima, A., Tian, R., Schwede, M., Alsop, K., Daniels, K., Piao, H., deFazio, A., et al (2012). Profiles of Genomic Instability in High-Grade Serous Ovarian Cancer Predict Treatment Outcome. Clinical Cancer Research, 18(20), 5806-5815. [More Information]

2011

  • Emmanuel, C., Gava, N., Kennedy, C., Balleine, R., Sharma, R., Wain, G., Brand, A., Hogg, R., Etemadmoghadam, D., George, J., Clarke, C., Harnett, P., deFazio, A., et al (2011). Comparison of Expression Profiles in Ovarian Epithelium In Vivo and Ovarian Cancer Identifies Novel Candidate Genes Involved in Disease Pathogenesis. PloS One, 6(3), e17617-1-e17617-18. [More Information]
  • Hunter, S., Anglesio, M., Sharma, R., Gilks, B., Melnyk, N., Chiew, Y., deFazio, A., Longacre, T., Huntsman, D., Gorringe, K., et al (2011). Copy Number Aberrations in Benign Serous Ovarian Tumors: A Case for Reclassification? Clinical Cancer Research, 17(23), 7273-7282. [More Information]
  • Helland, A., Anglesio, M., George, J., Cowin, P., Johnstone, C., House, C., Sheppard, K., Etemadmoghadam, D., Melnyk, N., Rustgi, A., deFazio, A., et al (2011). Deregulation of MYCN, LIN28B and LET7 in a Molecular Subtype of Aggressive High-Grade Serous Ovarian Cancers. PloS One, 6(4), 1-9. [More Information]
  • Anglesio, M., George, J., Kulbe, H., Friedlander, M., Rischin, D., Lemech, C., Power, J., Coward, J., Cowin, P., House, C., deFazio, A., et al (2011). IL6-STAT3-HIF Signaling and Therapeutic Response to the Angiogenesis Inhibitor Sunitinib in Ovarian Clear Cell Cancer. Clinical Cancer Research, 17(8), 2538-2548. [More Information]
  • Huang, S., Johnatty, S., Gamazon, E., Kyung Im, H., Ziliak, D., Duan, S., Zhang, W., O' Kistner, E., Chen, P., Beesley, J., deFazio, A., et al (2011). Platinum Sensitivity-Related Germline Polymorphism Discovered via a Cell-Based Approach and Analysis of Its Association with Outcome in Ovarian Cancer Patients. Clinical Cancer Research, 17(16), 5490-5500. [More Information]
  • Nagle, C., Francis, J., Nelson, A., Zorbas, H., Luxford, K., deFazio, A., Fereday, S., Bowtell, D., Green, A., Webb, P. (2011). Reducing Time to Diagnosis Does Not Improve Outcomes for Women With Symptomatic Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group. Journal of Clinical Oncology, 29(16), 2253-2258. [More Information]
  • McConechy, M., Anglesio, M., Kalloger, S., Yang, W., Senz, J., Chow, C., Heravi-Moussavi, A., Morin, G., deFazio, A., Mes-Masson, A., et al (2011). Subtype-specific mutation of PPP2R1A in endometrial and ovarian carcinomas. Journal of Pathology, 223(5), 567-573. [More Information]
  • Pharoah, P., Palmieri, R., Ramus, S., Gayther, S., Andrulis, I., Anton-Culver, H., Antonenkova, N., Antoniou, A., Goldgar, D., deFazio, A., Gao, B., Harnett, P., et al (2011). The Role of KRAS rs61764370 in Invasive Epithelial Ovarian Cancer: Implications for Clinical Testing. Clinical Cancer Research, 17(11), 3742-3750. [More Information]

2010

  • Johal, H., Faedo, M., Faltas, J., Lau, A., Mousina, R., Cozzi, P., deFazio, A., Rawlinson, W. (2010). DNA of mouse mammary tumor virus-like virus is present in human tumors influenced by hormones. Journal of Medical Virology, 82(6), 1044-1050. [More Information]
  • Ahmed Ashoure, A., Etemadmoghadam, D., Temple, J., Lynch, A., Riad, M., Sharma, R., Stewart, C., Fereday, S., Caldas, C., deFazio, A., et al (2010). Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. Journal of Pathology, 221(1), 49-56. [More Information]
  • Johnatty, S., Beesley, J., Chen, X., MacGregor, S., Duffy, D., Spurdle, A., deFazio, A., Gava, N., Webb, P., Rossing, M., et al (2010). Evaluation of candidate stromal epithelial cross-talk genes identifies association between risk of serous ovarian cancer and TERT, a cancer susceptibility "hot-spot". PLoS Genetics, 6(7), e1001016 - 1-e1001016 - 10. [More Information]
  • Hudson, T., Anderson, W., Aretz, A., Barker, A., Bell, C., Bernabe, R., Bhan, M., Calvo, F., Eerola, I., Gerhard, D., deFazio, A., Kench, J., et al (2010). International network of cancer genome projects. Nature, 464, 993-998. [More Information]
  • Byrne, J., Maleki, S., Hardy, J., Gloss, B., Murali, R., Scurry, J., Fanayan, S., Emmanuel, C., Hacker, N., Sutherland, R., deFazio, A., et al (2010). MAL2 and tumor protein D52 (TPD52) are frequently overexpressed in ovarian carcinoma, but differentially associated with histological subtype and patient outcome. BMC Cancer, 10(497), 1-11. [More Information]
  • Gordon, L., Scuffham, P., Beesley, V., Green, A., deFazio, A., Wyld, D., Clavarino, A., Australian Ovarian Cancer Study Group, (., Webb, P. (2010). Medical costs and outcomes for Australian women with ovarian cancer: a patient-level analysis over 2.5 years. International Journal of Gynecological Cancer, 20(5), 757-765. [More Information]
  • Price, M., Butow, P., Costa, D., King, M., Aldridge, L., Fardell, J., deFazio, A., Webb, P. (2010). Prevalence and predictors of anxiety and depression in women with invasive ovarian cancer and their caregivers. Medical Journal of Australia, 193(5), S52-S57. [More Information]

2009

  • Etemadmoghadam, D., deFazio, A., Beroukhim, R., Mermel, C., George, J., Getz, G., Tothill, R., Okamoto, A., Raeder, M., Harnett, P., Chiew, Y., et al (2009). Integrated genome-wide DMA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas. Clinical Cancer Research, 15(4), 1417-1427. [More Information]
  • Shah, S., Kobel, M., Senz, J., Morin, R., Clarke, B., Wiegand, K., Leung, G., Zayed, A., deFazio, A., Bowtell, D. (2009). Mutation of FOXL2 in granulosa-cell tumors of the ovary. New England Journal of Medicine, 360(26), 2719-2729. [More Information]
  • Johnatty, S., Beesley, J., Chen, X., Spurdle, A., deFazio, A., Webb, P., Goode, E., Rider, D., Vierkant, R., Anderson, S. (2009). Polymorphisms in the FGF2 Gene and Risk of Serous Ovarian Cancer: Results From the Ovarian Cancer Association Consortium. Twin Research and Human Genetics, 12(3), 269-275. [More Information]
  • Price, M., Zachariae, R., Butow, P., deFazio, A., Patel (nee Chauhan), D., Espie, C., Friedlander, M., Webb, P. (2009). Prevalence and predictors of insomnia in women with invasive ovarian cancer: Anxiety a major factor. European Journal of Cancer, 45(18), 3262-3270. [More Information]

2008

  • Johnatty, S., Beesley, J., Paul, J., Fereday, S., Spurdle, A., Webb, P., Byth, K., Marsh, S., McLeod, H., AOCS, S., Harnett, P., deFazio, A., et al (2008). ABCB1 (MDR 1) polymorphisms and progression-free survival among women with ovarian cancer following paclitaxel/carboplatin chemotherapy. Clinical Cancer Research, 14(17), 5594-5601.
  • Scurr, L., Guminski, A., Chiew, Y., Balleine, R., Sharma, R., Lei, Y., Pryor, K., Wain, G., Brand, A., Byth, K., Kennedy, C., Rizos, H., Harnett, P., deFazio, A. (2008). Ankyrin Repeat Domain 1, ANKRD1, a Novel Determinant of Cisplatin Sensitivity Expressed in Ovarian Cancer. Clinical Cancer Research, 14(21), 6924-6932. [More Information]
  • Gava, N., Clarke, C., Bye, C., Byth Wilson, K., deFazio, A. (2008). Global gene expression profiles of ovarian surface epithelial cells in vivo. Journal of Molecular Endocrinology, 40, 281-296. [More Information]
  • Anglesio, M., Arnold, J., George, J., Tinker, A., Tothill, R., Waddell, N., Simms, L., Locandro, B., Fereday, S., Traficante, N., Russell, P., deFazio, A., et al (2008). Mutation of ERBB2 provides a novel alternative mechanism for the ubiquitous activation of RAS-MAPK in ovarian serous low malignant potential tumors. Molecular Cancer Research, 6(11), 1678-1690. [More Information]
  • Tothill, R., Tinker, A., George, J., Brown, R., Fox, S., Lade, S., Johnson,, D., Trivett, M., Etemadmoghadam, D., Locandro, B., deFazio, A., et al (2008). Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clinical Cancer Research, 14(16), 5198-5208. [More Information]
  • O'Brien, P., Davies, M., Scurry, J., Smith, A., Barton, C., Henderson, M., Saunders, D., Gloss, B., Patterson, K., et, A., Murali, R., Scolyer, R., Scurr, L., deFazio, A. (2008). The E3 ubiquitin ligase EDD is an adverse prognostic factor for serous epithelial ovarian cancer and modulates cisplatin resistance in vitro. British Journal of Cancer, 98(6), 1085-1093. [More Information]

2007

  • Krypuy, M., Ahmed Ashoure, A., Etemadmoghadam, D., Hyland, S., deFazio, A., Fox, S., Brenton, J., Bowtell, D., Dobrovic, A. (2007). High resolution melting for mutation scanning of TP53 exons 5-8. BMC Cancer, 7(open access), 1-13. [More Information]
  • Greenman, C., Vastrik, I., Cahill, D., Goldstraw, P., Brasseur, F., Looijenga, L., Weber, B., Chiew, Y., deFazio, A., Greaves, M., et al (2007). Patterns of somatic mutation in human cancer genomes. Nature, 446(7132), 153-158. [More Information]
  • Catchpoole, D., deFazio, A., Devereaux, L., Hof, M., Schmidt, C., Thorne, H., Zeps, N., Fleming, M. (2007). The importance of biorepository networks: The Australasian Biospecimen Network-Oncology. Australian Journal of Medical Science, 28(1), 16-20.

2006

  • Guminski, A., Balleine, R., Chiew, Y., Webster, L., Tapner, M., Farrell, G., Harnett, P., deFazio, A. (2006). MRP2 (ABCC2) and cisplatin sensitivity in hepatocytes and human ovarian carcinoma. Gynecologic Oncology, 100(2), 239-246. [More Information]
  • Mote, P., Arnett-Mansfield, R., Gava, N., deFazio, A., Mulac-Jericevic, B., Conneely, O., Clarke, C. (2006). Overlapping and distinct expression of progesterone receptors A and B in mouse uterus and mammary gland during the estrous cycle. Endocrinology, 147(12), 5503-5512. [More Information]

2005

  • deFazio, A., Harnett, P., Guminski, A. (2005). Patent Families: Determinants of sensitivity to chemotherapeutic agents. Patent No. 2005316200.
  • Aghmesheh, M., Edwards, L., Clarke, C., Byth Wilson, K., Katzenellenbogen, B., Russell, P., Friedlander, M., Tucker, K., deFazio, A. (2005). Expression of steroid hormone receptors in BRCA1-associated ovarian carcinomas. Gynecologic Oncology, 97(1), 16-25. [More Information]
  • Byrne, J., Balleine, R., Fejzo, M., Mercieca, J., Chiew, Y., Livnat, Y., St.Heaps, L., Peters, G., Byth Wilson, K., Karlan, B., Harnett, P., deFazio, A., et al (2005). Tumor protein D52 (TPD52) is overexpressed and a gene amplification target in ovarian cancer. International Journal of Cancer, 117(6), 1049-54. [More Information]

2004

  • Balleine, R., Earls, P., Webster, L., Mote, P., deFazio, A., Harnett, P., Clarke, C. (2004). Expression Of Progesterone Receptor A And B Isoforms In Low-Grade Endometrial Stromal Sarcoma. International Journal of Gynecological Pathology, 23(2), 138-144.
  • Gava, N., Clarke, C., Byth Wilson, K., Arnett-Mansfield, R., deFazio, A. (2004). Expression Of Progesterone Receptors A And B In The Mouse Ovary During The Estrous Cycle. Endocrinology, 145(7), 3487-3494.
  • Arnett-Mansfield, R., deFazio, A., Mote, P., Clarke, C. (2004). Subnuclear Distribution Of Progesterone Receptors A And B In Normal And Malignant Endometrium. Journal of Clinical Endocrinology and Metabolism, 89(3), 1429-1442.

2001

  • Guminski, A., Harnett, P., deFazio, A. (2001). Carboplatin and paclitaxel interact antagonistically in a megakaryoblast cell line - a potential mechanism for paclitaxel-mediated sparing of carboplatin-induced thrombocytopenia. Cancer Chemotherapy and Pharmacology, 48(3), 229-234.
  • Guminski, A., deFazio, A., Harnett, P. (2001). New genetics and cancer chemotherapy. Today's Life Science (Australia), 13(2), 36-40.

2000

  • deFazio, A., Chiew, Y., Sini, R., Janes, P., Sutherland, R. (2000). Expression of c-erbB receptors, heregulin and oestrogen receptor in human breast cell lines. International Journal of Cancer, 87(4), 487-498.
  • Davis, T., Kennedy, C., Chiew, Y., Clarke, C., deFazio, A. (2000). Histone deacetylase inhibitors decrease proliferation and modulate cell cycle gene expression in normal mammary epithelial cells. Clinical Cancer Research, 6(11), 4334-4342.

To update your profile click here. For support on your academic profile contact .